Amgen Provides Ambitious Update On Biosimilars Business
CEO Says Company Expects To Double Biosimilar Revenues To Around $4bn By 2030
Executive Summary
Amgen CEO Robert Bradway has delivered confident predictions for the company’s biosimilars business at the J.P. Morgan Healthcare Conference, with a steady flow of launches expected to give the company’s earnings a significant boost over the coming years.
You may also be interested in...
Generics Bulletin Editor’s Picks For Q1 2022
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.
Amgen’s Growth Story Relies Mainly On Continuing Plot Lines
Established brands Repatha and Otezla, new launches Lumakras and Tezspire, and the Amjevita-led biosimilars portfolio will provide most of the company’s growth through the end of this decade.
Q4 Earnings Preview: Setting The Tone For 2022 (Part 1)
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.